Achillion Pharmaceuticals, Inc. ACHN announced that it has initiated a phase I study on its next-generation, oral, alternative pathway factor D inhibitor, ACH-5548. Interim data from the same is ...

All the Latest Game Footage and Images from Factor D Manga-style 2d turn-based fighting game, choose 1 character among the 12, with different endings for each one, discover the story by winning ...

Achillion Pharmaceuticals, Inc. ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors – ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are ...

It acquired both of these drugs via its US$39 billion buyout of Alexion in 2021. Other factor D inhibitors in clinical development include AstraZeneca’s ALXN2080 and BioCryst’s BCX-10013.

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).